 | • レポートコード：GIR-22F19602 • 出版社/出版日：GlobalInfoResearch / 2022年11月 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「Global Retinal Vasculitis Treatment Market 2022」レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 グローバルインフォリサーチ社の最新の調査によると、世界の網膜血管炎治療の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 網膜血管炎治療市場はタイプ（種類）とアプリケーション（用途）によって区分されます。2017年～2028年において、量と金額の観点からタイプ別およびアプリケーション別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 タイプ別セグメントは次をカバーします。 ・免疫抑制剤、コルチコステロイド剤 アプリケーション別セグメントは次のように区分されます。 ・病院、診療所、その他 世界の網膜血管炎治療市場の主要な市場プレーヤーは以下のとおりです。 ・Celgene Corporation、Merck & Co、Novartis AG、F. Hoffmann-La Roche、GlaxoSmithKline plc、Bristol-Myers Squibb Company、RNL BIO Co., Ltd.、Teijin Pharma Limited、Anthera Pharmaceuticals、Human Genome Sciences, Inc.、Novo Nordisk A/S、Eli Lilly and Company 地域別セグメントは次の地域・国をカバーします。 ・北米市場（米国、カナダ、メキシコ） ・ヨーロッパ市場（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋市場（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南米市場（ブラジル、アルゼンチン、コロンビア） ・中東・アフリカ市場（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、網膜血管炎治療製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要な網膜血管炎治療メーカーの企業概要、2019年～2022年までの網膜血管炎治療の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要な網膜血管炎治療メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別網膜血管炎治療の販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までの網膜血管炎治療のタイプ別とアプリケーション別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での網膜血管炎治療市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、および網膜血管炎治療の産業チェーンを掲載しています。 ・第13、14、15章では、網膜血管炎治療の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 - 網膜血管炎治療の概要 - タイプ別分析（2017年vs2021年vs2028年）：免疫抑制剤、コルチコステロイド剤 - アプリケーション別分析（2017年vs2021年vs2028年）：病院、診療所、その他 - 世界の網膜血管炎治療市場規模・予測 - 世界の網膜血管炎治療生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Celgene Corporation、Merck & Co、Novartis AG、F. Hoffmann-La Roche、GlaxoSmithKline plc、Bristol-Myers Squibb Company、RNL BIO Co., Ltd.、Teijin Pharma Limited、Anthera Pharmaceuticals、Human Genome Sciences, Inc.、Novo Nordisk A/S、Eli Lilly and Company ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・タイプ別分析2017年-2028年：免疫抑制剤、コルチコステロイド剤 ・アプリケーション別分析2017年-2028年：病院、診療所、その他 ・網膜血管炎治療の北米市場分析 - 網膜血管炎治療の北米市場：タイプ別市場規模2017年-2028年 - 網膜血管炎治療の北米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・網膜血管炎治療のヨーロッパ市場分析 - ：網膜血管炎治療のヨーロッパ市場：タイプ別市場規模2017年-2028年 - ：網膜血管炎治療のヨーロッパ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・網膜血管炎治療のアジア太平洋市場分析 - 網膜血管炎治療のアジア太平洋市場：タイプ別市場規模2017年-2028年 - 網膜血管炎治療のアジア太平洋市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・網膜血管炎治療の南米市場分析 - 網膜血管炎治療の南米市場：タイプ別市場規模2017年-2028年 - 網膜血管炎治療の南米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・網膜血管炎治療の中東・アフリカ市場分析 - 網膜血管炎治療の中東・アフリカ市場：タイプ別市場規模2017年-2028年 - 網膜血管炎治療の中東・アフリカ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Retinal Vasculitis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Retinal Vasculitis Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospital accounting for % of the Retinal Vasculitis Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Immunosuppressive Drug segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Retinal Vasculitis Treatment include Celgene Corporation, Merck & Co, Novartis AG, F. Hoffmann-La Roche, and GlaxoSmithKline plc, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Retinal Vasculitis Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Immunosuppressive Drug
corticosteroid Drug
Market segment by Application can be divided into
Hospital
Clinic
Others
The key market players for global Retinal Vasculitis Treatment market are listed below:
Celgene Corporation
Merck & Co
Novartis AG
F. Hoffmann-La Roche
GlaxoSmithKline plc
Bristol-Myers Squibb Company
RNL BIO Co., Ltd.
Teijin Pharma Limited
Anthera Pharmaceuticals
Human Genome Sciences, Inc.
Novo Nordisk A/S
Eli Lilly and Company
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Retinal Vasculitis Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Retinal Vasculitis Treatment, with price, sales, revenue and global market share of Retinal Vasculitis Treatment from 2019 to 2022.
Chapter 3, the Retinal Vasculitis Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Retinal Vasculitis Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Retinal Vasculitis Treatment market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Retinal Vasculitis Treatment.
Chapter 13, 14, and 15, to describe Retinal Vasculitis Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Retinal Vasculitis Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Retinal Vasculitis Treatment Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Immunosuppressive Drug
1.2.3 corticosteroid Drug
1.3 Market Analysis by Application
1.3.1 Overview: Global Retinal Vasculitis Treatment Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Retinal Vasculitis Treatment Market Size & Forecast
1.4.1 Global Retinal Vasculitis Treatment Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Retinal Vasculitis Treatment Sales in Volume (2017-2028)
1.4.3 Global Retinal Vasculitis Treatment Price (2017-2028)
1.5 Global Retinal Vasculitis Treatment Production Capacity Analysis
1.5.1 Global Retinal Vasculitis Treatment Total Production Capacity (2017-2028)
1.5.2 Global Retinal Vasculitis Treatment Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Retinal Vasculitis Treatment Market Drivers
1.6.2 Retinal Vasculitis Treatment Market Restraints
1.6.3 Retinal Vasculitis Treatment Trends Analysis
2 Manufacturers Profiles
2.1 Celgene Corporation
2.1.1 Celgene Corporation Details
2.1.2 Celgene Corporation Major Business
2.1.3 Celgene Corporation Retinal Vasculitis Treatment Product and Services
2.1.4 Celgene Corporation Retinal Vasculitis Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Merck & Co
2.2.1 Merck & Co Details
2.2.2 Merck & Co Major Business
2.2.3 Merck & Co Retinal Vasculitis Treatment Product and Services
2.2.4 Merck & Co Retinal Vasculitis Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Novartis AG
2.3.1 Novartis AG Details
2.3.2 Novartis AG Major Business
2.3.3 Novartis AG Retinal Vasculitis Treatment Product and Services
2.3.4 Novartis AG Retinal Vasculitis Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 F. Hoffmann-La Roche
2.4.1 F. Hoffmann-La Roche Details
2.4.2 F. Hoffmann-La Roche Major Business
2.4.3 F. Hoffmann-La Roche Retinal Vasculitis Treatment Product and Services
2.4.4 F. Hoffmann-La Roche Retinal Vasculitis Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 GlaxoSmithKline plc
2.5.1 GlaxoSmithKline plc Details
2.5.2 GlaxoSmithKline plc Major Business
2.5.3 GlaxoSmithKline plc Retinal Vasculitis Treatment Product and Services
2.5.4 GlaxoSmithKline plc Retinal Vasculitis Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Bristol-Myers Squibb Company
2.6.1 Bristol-Myers Squibb Company Details
2.6.2 Bristol-Myers Squibb Company Major Business
2.6.3 Bristol-Myers Squibb Company Retinal Vasculitis Treatment Product and Services
2.6.4 Bristol-Myers Squibb Company Retinal Vasculitis Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 RNL BIO Co., Ltd.
2.7.1 RNL BIO Co., Ltd. Details
2.7.2 RNL BIO Co., Ltd. Major Business
2.7.3 RNL BIO Co., Ltd. Retinal Vasculitis Treatment Product and Services
2.7.4 RNL BIO Co., Ltd. Retinal Vasculitis Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Teijin Pharma Limited
2.8.1 Teijin Pharma Limited Details
2.8.2 Teijin Pharma Limited Major Business
2.8.3 Teijin Pharma Limited Retinal Vasculitis Treatment Product and Services
2.8.4 Teijin Pharma Limited Retinal Vasculitis Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Anthera Pharmaceuticals
2.9.1 Anthera Pharmaceuticals Details
2.9.2 Anthera Pharmaceuticals Major Business
2.9.3 Anthera Pharmaceuticals Retinal Vasculitis Treatment Product and Services
2.9.4 Anthera Pharmaceuticals Retinal Vasculitis Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Human Genome Sciences, Inc.
2.10.1 Human Genome Sciences, Inc. Details
2.10.2 Human Genome Sciences, Inc. Major Business
2.10.3 Human Genome Sciences, Inc. Retinal Vasculitis Treatment Product and Services
2.10.4 Human Genome Sciences, Inc. Retinal Vasculitis Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Novo Nordisk A/S
2.11.1 Novo Nordisk A/S Details
2.11.2 Novo Nordisk A/S Major Business
2.11.3 Novo Nordisk A/S Retinal Vasculitis Treatment Product and Services
2.11.4 Novo Nordisk A/S Retinal Vasculitis Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Eli Lilly and Company
2.12.1 Eli Lilly and Company Details
2.12.2 Eli Lilly and Company Major Business
2.12.3 Eli Lilly and Company Retinal Vasculitis Treatment Product and Services
2.12.4 Eli Lilly and Company Retinal Vasculitis Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Retinal Vasculitis Treatment Breakdown Data by Manufacturer
3.1 Global Retinal Vasculitis Treatment Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Retinal Vasculitis Treatment Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Retinal Vasculitis Treatment
3.4 Market Concentration Rate
3.4.1 Top 3 Retinal Vasculitis Treatment Manufacturer Market Share in 2021
3.4.2 Top 6 Retinal Vasculitis Treatment Manufacturer Market Share in 2021
3.5 Global Retinal Vasculitis Treatment Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Retinal Vasculitis Treatment Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Retinal Vasculitis Treatment Market Size by Region
4.1.1 Global Retinal Vasculitis Treatment Sales in Volume by Region (2017-2028)
4.1.2 Global Retinal Vasculitis Treatment Revenue by Region (2017-2028)
4.2 North America Retinal Vasculitis Treatment Revenue (2017-2028)
4.3 Europe Retinal Vasculitis Treatment Revenue (2017-2028)
4.4 Asia-Pacific Retinal Vasculitis Treatment Revenue (2017-2028)
4.5 South America Retinal Vasculitis Treatment Revenue (2017-2028)
4.6 Middle East and Africa Retinal Vasculitis Treatment Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Retinal Vasculitis Treatment Sales in Volume by Type (2017-2028)
5.2 Global Retinal Vasculitis Treatment Revenue by Type (2017-2028)
5.3 Global Retinal Vasculitis Treatment Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Retinal Vasculitis Treatment Sales in Volume by Application (2017-2028)
6.2 Global Retinal Vasculitis Treatment Revenue by Application (2017-2028)
6.3 Global Retinal Vasculitis Treatment Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Retinal Vasculitis Treatment Sales by Type (2017-2028)
7.2 North America Retinal Vasculitis Treatment Sales by Application (2017-2028)
7.3 North America Retinal Vasculitis Treatment Market Size by Country
7.3.1 North America Retinal Vasculitis Treatment Sales in Volume by Country (2017-2028)
7.3.2 North America Retinal Vasculitis Treatment Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Retinal Vasculitis Treatment Sales by Type (2017-2028)
8.2 Europe Retinal Vasculitis Treatment Sales by Application (2017-2028)
8.3 Europe Retinal Vasculitis Treatment Market Size by Country
8.3.1 Europe Retinal Vasculitis Treatment Sales in Volume by Country (2017-2028)
8.3.2 Europe Retinal Vasculitis Treatment Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Retinal Vasculitis Treatment Sales by Type (2017-2028)
9.2 Asia-Pacific Retinal Vasculitis Treatment Sales by Application (2017-2028)
9.3 Asia-Pacific Retinal Vasculitis Treatment Market Size by Region
9.3.1 Asia-Pacific Retinal Vasculitis Treatment Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Retinal Vasculitis Treatment Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Retinal Vasculitis Treatment Sales by Type (2017-2028)
10.2 South America Retinal Vasculitis Treatment Sales by Application (2017-2028)
10.3 South America Retinal Vasculitis Treatment Market Size by Country
10.3.1 South America Retinal Vasculitis Treatment Sales in Volume by Country (2017-2028)
10.3.2 South America Retinal Vasculitis Treatment Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Retinal Vasculitis Treatment Sales by Type (2017-2028)
11.2 Middle East & Africa Retinal Vasculitis Treatment Sales by Application (2017-2028)
11.3 Middle East & Africa Retinal Vasculitis Treatment Market Size by Country
11.3.1 Middle East & Africa Retinal Vasculitis Treatment Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Retinal Vasculitis Treatment Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Retinal Vasculitis Treatment and Key Manufacturers
12.2 Manufacturing Costs Percentage of Retinal Vasculitis Treatment
12.3 Retinal Vasculitis Treatment Production Process
12.4 Retinal Vasculitis Treatment Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Retinal Vasculitis Treatment Typical Distributors
13.3 Retinal Vasculitis Treatment Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer